Home » Healthcare » Australia Addiction Treatment Market

Australia Addiction Treatment Market By Treatment Type(Alcohol Addiction Treatment ,Tobacco/Nicotine Addiction Treatment ,Opioid Addiction Treatment, Other Substances Addiction Treatment)By Drug Type(Bupropion, Varenicline, Acamprosate, Disulfiram, Naltrexone, Methadone ,Buprenorphine ,Nicotine Replacement Products, Others) By Based on Treatment Centre (Outpatient Treatment Centers, Residential Treatment Centers, Inpatient Treatment Centers) By Based on Distribution Channel (Hospitals Pharmacies, Medical Stores, Others) – Growth, Future Prospects & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Australia Addiction Treatment Market Size 2023	USD 78.44 million
Australia Addiction Treatment Market, CAGR	7.24%
Australia Addiction Treatment Market Size 2032	USD 149.42 million

Market Overview

The Australia Addiction Treatment Market is projected to grow from USD 78.44 million in 2023 to an estimated USD 149.42 million by 2032, with a compound annual growth rate (CAGR) of 7.24% from 2024 to 2032. This significant growth is driven by increasing awareness about addiction issues, expanding government initiatives, and rising demand for effective treatment options.

Key drivers fueling the market include advancements in treatment methodologies, integration of technology in treatment programs, and increasing prevalence of substance abuse disorders. Trends such as the adoption of telemedicine for addiction treatment and the rising preference for outpatient rehabilitation services are also contributing to market growth. Additionally, growing societal acceptance and destigmatization of seeking addiction treatment have positively impacted market dynamics

Geographically, the market analysis indicates that major urban centers like Sydney, Melbourne, and Brisbane are leading in the adoption of advanced addiction treatment services due to better healthcare infrastructure and higher awareness levels. Key players in the Australia addiction treatment market include Ramsay Health Care, The Cabin Sydney, and DayHab, which are continually innovating and expanding their service offerings to meet the increasing demand. These companies are instrumental in shaping the market landscape through strategic initiatives and collaborations aimed at enhancing treatment accessibility and efficacy.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Drivers

Increasing Awareness and Acceptance of Addiction as a Medical Condition

One of the most critical drivers of the Australia addiction treatment market is the growing awareness and acceptance of addiction as a medical condition rather than a moral failing. This shift in perception is largely due to extensive public health campaigns and educational programs highlighting the neurological and psychological underpinnings of addiction. For instance, the National Tobacco Campaign in Australia aims to reduce smoking rates and is part of the National Tobacco Strategy. As a result, there is a reduced stigma associated with seeking treatment, encouraging more individuals to access necessary services. The media and advocacy groups have played a substantial role in reshaping public attitudes towards addiction. Stories of recovery and expert discussions in various forums have humanized those struggling with addiction, promoting empathy and understanding. Additionally, the medical community’s recognition of addiction as a chronic disease has led to more comprehensive and scientifically-backed treatment approaches. This societal shift is crucial as it directly influences the demand for addiction treatment services, contributing to market growth.

Advancements in Treatment Methodologies

The evolution of treatment methodologies is another significant driver of the Australia addiction treatment market. Traditional approaches to addiction treatment have been augmented by innovative techniques that improve patient outcomes. These advancements include the development of evidence-based therapies, personalized treatment plans, and the integration of holistic approaches. Evidence-based therapies, such as cognitive-behavioral therapy (CBT), contingency management, and motivational interviewing, have been proven effective in treating various forms of addiction. For instance, the current evidence-based guidelines in Australia suggest that the integrated treatment of mental health and AOD use disorders is best practice. These therapies are often combined with medication-assisted treatment (MAT), which uses FDA-approved medications to manage withdrawal symptoms and reduce cravings. MAT has shown particular efficacy in treating opioid and alcohol dependence, providing patients with a more stable and supportive path to recovery. Personalized treatment plans have also gained traction, with healthcare providers tailoring interventions to meet the unique needs of each individual. This approach considers factors such as the type of substance abused, the duration and severity of addiction, and any co-occurring mental health conditions. By addressing the specific circumstances of each patient, personalized plans enhance the likelihood of successful outcomes. Holistic approaches, which incorporate physical, emotional, and spiritual elements into the treatment process, have also become more prevalent. Techniques such as mindfulness meditation, yoga, and art therapy are being integrated into traditional treatment programs, providing patients with additional tools to manage stress and prevent relapse.

Government Initiatives and Funding

Government initiatives and funding are pivotal in driving the growth of the addiction treatment market in Australia. Recognizing the widespread impact of substance abuse on public health and safety, federal and state governments have increased their investment in addiction treatment programs and services. These initiatives aim to expand access to treatment, improve the quality of care, and support ongoing research into effective interventions. For instance, the Australian Government has developed plans and strategies, funded programs and research, and worked with other organisations to help reduce the harmful effects of drugs in Australia. One key aspect of government involvement is the allocation of funds for community-based treatment centers. These centers provide accessible and affordable services to individuals in both urban and rural areas, ensuring that a broader population can receive the help they need. Government funding also supports training programs for healthcare professionals, equipping them with the skills necessary to deliver high-quality addiction treatment. In addition to funding, legislative measures have been enacted to support individuals seeking treatment. Policies that promote early intervention, harm reduction, and recovery support services have been implemented to create a more comprehensive and supportive treatment infrastructure. For example, needle exchange programs, supervised injection sites, and naloxone distribution initiatives aim to reduce the immediate harms associated with substance use and encourage individuals to enter treatment.

Integration of Technology in Addiction Treatment

The integration of technology in addiction treatment is transforming the way services are delivered and accessed. Telemedicine, mobile health applications, and online support groups have become increasingly popular, particularly in the wake of the COVID-19 pandemic. These technological advancements provide several benefits, including increased accessibility, convenience, and continuity of care. Telemedicine allows patients to receive counseling and support from the comfort of their own homes, breaking down barriers related to geography, transportation, and scheduling. This is particularly beneficial for individuals in remote or underserved areas who may otherwise have limited access to treatment. Telemedicine also offers a level of anonymity that can reduce the stigma associated with seeking help, encouraging more individuals to engage in treatment. Mobile health applications provide patients with tools to monitor their progress, manage cravings, and connect with support networks. These apps often include features such as tracking sobriety milestones, setting reminders for medication or therapy sessions, and accessing educational resources. By empowering patients to take an active role in their recovery, these technologies enhance engagement and adherence to treatment plans. Online support groups and virtual meetings have also gained popularity, offering a sense of community and connection for individuals in recovery. These platforms provide a space for sharing experiences, offering encouragement, and receiving peer support, which are all critical components of the recovery process.

Market Trends

Adoption of Integrated Treatment Models

The adoption of integrated treatment models is a prominent trend in the Australia addiction treatment market. Integrated treatment involves a comprehensive approach that addresses not only the addiction but also any co-occurring mental health disorders. This model recognizes the complex interplay between addiction and mental health, ensuring that both conditions are treated simultaneously for better patient outcomes. For instance, the National Framework for Alcohol, Tobacco and Other Drug Treatment in Australia aims to ensure that all Australians seeking alcohol and other drug treatment can access high-quality treatment appropriate to their needs. Integrated treatment models often combine traditional therapies, such as cognitive-behavioral therapy (CBT) and medication-assisted treatment (MAT), with holistic and alternative approaches like mindfulness, yoga, and art therapy. By addressing the physical, psychological, and emotional aspects of addiction, these models provide a more rounded and effective treatment experience. This trend is driven by the growing body of evidence supporting the efficacy of integrated care in achieving long-term recovery and reducing relapse rates. Furthermore, the rise in dual diagnosis cases—where patients suffer from both substance use disorders and mental health conditions like depression or anxiety—has made integrated treatment models increasingly relevant. Healthcare providers are now more equipped and inclined to offer these comprehensive services, ensuring that patients receive the most appropriate and effective care tailored to their individual needs.

Expansion of Telehealth and Digital Health Solutions

The expansion of telehealth and digital health solutions is another significant trend shaping the Australia addiction treatment market. The COVID-19 pandemic accelerated the adoption of telehealth, making remote treatment options more prevalent and accepted. For instance, between 13 March 2020 and 31 July 2022, 118.2 million telehealth services have been delivered to 18 million patients in Australia. Telehealth services offer numerous advantages, including increased accessibility, flexibility, and privacy for patients seeking addiction treatment. Telehealth platforms allow patients to access counseling, therapy sessions, and support groups from the comfort of their own homes, overcoming geographical and logistical barriers. This is particularly beneficial for individuals in rural or remote areas who may have limited access to in-person treatment facilities. Additionally, telehealth provides a level of anonymity that can reduce the stigma associated with seeking addiction treatment, encouraging more individuals to seek help. Digital health solutions, such as mobile health apps and online support communities, are also gaining traction. These tools offer patients a variety of resources to support their recovery journey, including tracking sobriety milestones, managing cravings, and connecting with peer support networks. Mobile apps can provide real-time interventions and reminders, helping individuals stay on track with their treatment plans. The integration of artificial intelligence (AI) and machine learning in digital health solutions is another emerging trend. AI-powered platforms can offer personalized treatment recommendations based on patient data, predict relapse risks, and provide timely interventions. These technologies enhance the effectiveness and efficiency of addiction treatment, making it more responsive to the needs of individual patients.

Market Restraints and Challenges

Limited Access to Treatment Facilities and Resources

One of the primary restraints in the Australia addiction treatment market is the limited access to treatment facilities and resources, particularly in rural and remote areas. Despite the increasing awareness and demand for addiction treatment services, there are significant disparities in the availability of quality care across different regions. Many rural communities lack the necessary infrastructure, trained healthcare professionals, and specialized treatment centers, making it challenging for individuals in these areas to access the care they need. This geographical disparity results in longer waiting times for treatment, reduced options for specialized care, and increased travel burdens for patients seeking help. Additionally, the shortage of trained addiction specialists and healthcare providers exacerbates the problem, as the existing workforce is often concentrated in urban centers. This limited access not only delays the initiation of treatment but also affects the continuity and effectiveness of care, ultimately hindering the overall progress in addressing addiction issues nationwide.

Stigma and Social Barriers

Stigma and social barriers continue to pose significant challenges to the Australia addiction treatment market. Despite growing awareness about addiction as a medical condition, societal stigma and negative perceptions around addiction and treatment remain prevalent. This stigma discourages individuals from seeking help due to fear of judgment, discrimination, and social exclusion. As a result, many individuals with addiction issues delay or avoid seeking treatment, which can lead to worsening conditions and more complex health problems. The stigma is often reinforced by media portrayals, cultural attitudes, and misinformation about addiction and recovery. This social barrier not only affects individuals but also impacts families and communities, creating an environment where addiction is not openly discussed or addressed. Efforts to reduce stigma through public education campaigns, advocacy, and community engagement are crucial, but progress is often slow and uneven. In addition to societal stigma, structural barriers such as inadequate insurance coverage and high out-of-pocket costs for treatment further limit access to care. Many individuals find it challenging to afford comprehensive treatment programs, leading to interruptions in care and lower chances of successful recovery. Addressing these financial and social barriers is essential to ensuring that more individuals can access the support and treatment they need to overcome addiction.

Market Segmentation Analysis

By Treatment Type

The Australia addiction treatment market is composed of several key segments, each driven by different factors. Alcohol addiction treatment remains the largest segment, supported by the high prevalence of alcohol use disorders and the availability of various treatment options such as detoxification, counseling, medication-assisted treatment (MAT), and support groups like Alcoholics Anonymous (AA). The growth of this segment is further fueled by increasing awareness and social acceptance of seeking help for alcohol addiction. Tobacco and nicotine addiction treatment is also significant, driven by high addiction rates and the effectiveness of treatments like behavioral therapy, nicotine replacement therapy (NRT), and medications such as bupropion and varenicline. Public health campaigns and regulatory measures against smoking have bolstered demand in this segment. The opioid addiction treatment segment is expanding rapidly due to rising opioid misuse and dependence, with effective treatments including MAT with methadone, buprenorphine, and naltrexone, supported by behavioral therapies and government initiatives targeting the opioid crisis. Lastly, the segment for other substances addiction treatment addresses a wide range of addictions, including cannabis, stimulants, and prescription drugs, with comprehensive treatment programs that reflect the complex nature of substance use disorders and are increasingly in demand.

By Drug Type

Key medications in the Australia addiction treatment market include bupropion, varenicline, acamprosate, disulfiram, naltrexone, methadone, buprenorphine, and nicotine replacement products. Bupropion and varenicline are primarily used for tobacco cessation, effectively reducing withdrawal symptoms and cravings. Acamprosate and disulfiram support alcohol addiction treatment by maintaining abstinence and discouraging drinking through adverse effects. Naltrexone is versatile, treating both alcohol and opioid dependence by blocking euphoric effects, thus aiding in relapse prevention. Methadone and buprenorphine are crucial in opioid addiction treatment, mitigating withdrawal symptoms and cravings. Nicotine replacement products, such as patches, gums, and lozenges, manage nicotine withdrawal and are widely accessible. The category of “others” includes emerging medications and adjunctive therapies, showcasing ongoing research and innovation in addiction treatment.

Segments

Based on Treatment Type

Alcohol Addiction Treatment
Tobacco/Nicotine Addiction Treatment
Opioid Addiction Treatment
Other Substances Addiction Treatment

Based on Drug Type

Bupropion
Varenicline
Acamprosate
Disulfiram
Naltrexone
Methadone
Buprenorphine
Nicotine Replacement Products
Others

Based on Treatment Centre

Outpatient Treatment Centers
Residential Treatment Centers
Inpatient Treatment Centers

Based on Distribution Channel

Hospitals Pharmacies
Medical Stores
Others

Based on Region

Urban Areas
Rural Areas

Regional Analysis

New South Wales (28%):

New South Wales (NSW) holds a significant share of the Australia addiction treatment market, accounting for approximately 28% of the total market. This dominance is attributed to the state’s large population and the presence of numerous addiction treatment facilities, particularly in Sydney. NSW has seen substantial government investment in healthcare infrastructure and public health campaigns aimed at reducing substance abuse. The state offers a wide range of services, from detoxification and outpatient programs to residential rehabilitation centers, making it a comprehensive hub for addiction treatment.

Victoria (25%):

Victoria is another major player in the addiction treatment market, contributing around 25% to the national market share. Melbourne, the state’s capital, is known for its advanced healthcare services and numerous specialized addiction treatment centers. The Victorian government has been proactive in addressing addiction issues through various initiatives, including harm reduction strategies, needle exchange programs, and extensive support for mental health services. This integrated approach has made Victoria a leader in providing effective and accessible addiction treatment.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key players

Teva Pharmaceutical Industries Ltd.
Pfizer, Inc.
Glenmark Pharmaceuticals
GSK plc
Johnson & Johnson Services, Inc.
Novartis AG
Cipla
Reddy Laboratories Limited
Mylan N.V.
Eli Lilly and Company

Competitive Analysis

The Australia addiction treatment market is highly competitive, with key players leveraging their extensive research and development capabilities to introduce innovative treatment options. Teva Pharmaceutical Industries Ltd. and Pfizer, Inc. are leading the market with their strong portfolios of addiction treatment medications. Glenmark Pharmaceuticals and GSK plc are recognized for their effective therapies targeting various types of substance dependencies. Johnson & Johnson Services, Inc. and Novartis AG continue to enhance their market presence through strategic acquisitions and partnerships. Cipla and Dr. Reddy Laboratories Limited are notable for their affordable generic medications, making treatment more accessible. Mylan N.V. and Eli Lilly and Company are also key contributors, focusing on advancing treatment efficacy and patient outcomes. These companies are engaged in continuous efforts to expand their market share by investing in clinical trials, regulatory approvals, and marketing strategies to address the growing demand for addiction treatment services in Australia.

Recent Developments

In February 2024, Roche Pharma India expanded its neurology portfolio by introducing Ocrevus (ocrelizumab) for the treatment of multiple sclerosis (MS). This medication is the first and only approved disease-modifying treatment for both primary progressive multiple sclerosis (PPMS) and relapsing-remitting multiple sclerosis (RRMS). This expansion aims to address the unmet needs of patients suffering from these conditions, providing a comprehensive solution to manage and modify the progression of MS.

In March 2024, Dr. Reddy’s Laboratories announced the availability of Versavo (bevacizumab) for treating various cancer types in the UK. Comparable to Avastin, Versavo is approved for metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer, and metastatic breast cancer. This introduction marks a significant step in providing affordable and effective treatment options for these critical conditions.

In January 2023, Hikma Pharmaceuticals PLC launched Naloxone Hydrochloride Injection, USP, 2mg/2mL, in prefilled syringe (PFS) form. This medication is designed for the emergency treatment of known or suspected opioid overdoses and represents the company’s third PFS product launch. The introduction of this life-saving drug underscores Hikma’s commitment to addressing the opioid crisis with effective and accessible solutions.

In March 2023, Indivior PLC made significant strides in the addiction treatment market by acquiring Opiant Pharmaceuticals, Inc. This strategic acquisition enhances Indivior’s product portfolio and pipeline, including new candidates for treating alcohol use disorder and cannabinoid overdose. This development aligns with Indivior’s mission to meet the evolving needs of patients with substance use disorders (SUD), further solidifying its position as a leader in addiction treatment.

Market Concentration and Characteristics

The Australia addiction treatment market is characterized by a moderate to high market concentration, with a few key players dominating the landscape. Leading pharmaceutical companies such as Teva Pharmaceutical Industries Ltd., Pfizer, Inc., and GSK plc, among others, have established a strong presence through extensive research, development, and strategic acquisitions. The market is defined by a diverse range of treatment options, including medications, counseling services, and holistic approaches, catering to various types of substance dependencies. Innovations in telehealth and integrated treatment models also shape the market, addressing both urban and rural needs, and ensuring comprehensive care for patients across the country.

Report Coverage

The research report offers an in-depth analysis based on Treatment Type, Drug Type, Treatment Centre, Distribution Channel and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The integration of telehealth and mobile health applications will continue to expand, enhancing accessibility and providing innovative ways to deliver addiction treatment remotely.

Increased government funding and policy initiatives will bolster the development and availability of comprehensive addiction treatment programs across Australia.

Ongoing public health campaigns will further reduce the stigma associated with addiction, encouraging more individuals to seek treatment and support.

Advancements in personalized medicine will lead to more tailored treatment approaches, improving outcomes by addressing the specific needs of each patient.

The establishment of new outpatient, residential, and inpatient treatment centers, especially in underserved areas, will improve access to addiction treatment services.

The incorporation of holistic therapies, such as mindfulness, yoga, and art therapy, will become more prevalent, providing additional support for patients’ overall well-being.

Continued investment in research and development will lead to the discovery of new medications and therapies, enhancing the effectiveness of addiction treatments.

Increased collaboration between public, private, and non-profit sectors will strengthen the addiction treatment infrastructure, ensuring a more coordinated and effective response.

Greater emphasis on the integration of mental health services with addiction treatment will address co-occurring disorders, providing a more comprehensive approach to recovery.

The Australian market will benefit from global trends and innovations in addiction treatment, adopting best practices and cutting-edge technologies from around the world.

CHAPTER NO. 1 : INTRODUCTION 14

1.1.1. Report Description 14

Purpose of the Report 14

USP & Key Offerings 14

1.1.2. Key Benefits for Stakeholders 14

1.1.3. Target Audience 15

1.1.4. Report Scope 15

CHAPTER NO. 2 : EXECUTIVE SUMMARY 16

2.1. Australia Addiction Treatment Market Snapshot 16

2.1.1. Australia Addiction Treatment Market, 2018 – 2032 (USD Million) 17

CHAPTER NO. 3 : AUSTRALIA ADDICTION TREATMENT MARKET – INDUSTRY ANALYSIS 18

3.1. Introduction 18

3.2. Market Drivers 19

3.2.1. Driving Factor 1 Analysis 19

3.2.2. Driving Factor 2 Analysis 20

3.3. Market Restraints 21

3.3.1. Restraining Factor Analysis 21

3.4. Market Opportunities 22

3.4.1. Market Opportunity Analysis 22

3.5. Porter’s Five Forces Analysis 23

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 24

4.1. Company Market Share Analysis – 2023 24

4.1.1. Australia Addiction Treatment Market: Company Market Share, by Volume, 2023 24

4.1.2. Australia Addiction Treatment Market: Company Market Share, by Revenue, 2023 25

4.1.3. Australia Addiction Treatment Market: Top 6 Company Market Share, by Revenue, 2023 25

4.1.4. Australia Addiction Treatment Market: Top 3 Company Market Share, by Revenue, 2023 26

4.2. Australia Addiction Treatment Market Company Revenue Market Share, 2023 27

4.3. Company Assessment Metrics, 2023 28

4.3.1. Stars 28

4.3.2. Emerging Leaders 28

4.3.3. Pervasive Players 28

4.3.4. Participants 28

4.4. Start-ups /SMEs Assessment Metrics, 2023 28

4.4.1. Progressive Companies 28

4.4.2. Responsive Companies 28

4.4.3. Dynamic Companies 28

4.4.4. Starting Blocks 28

4.5. Strategic Developments 29

4.5.1. Acquisitions & Mergers 29

New Product Launch 29

Australia Expansion 29

4.6. Key Players Product Matrix 30

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 31

5.1. PESTEL 31

5.1.1. Political Factors 31

5.1.2. Economic Factors 31

5.1.3. Social Factors 31

5.1.4. Technological Factors 31

5.1.5. Environmental Factors 31

5.1.6. Legal Factors 31

5.2. Adjacent Market Analysis 31

CHAPTER NO. 6 : AUSTRALIA ADDICTION TREATMENT MARKET – BY TREATMENT TYPE SEGMENT ANALYSIS 32

6.1. Australia Addiction Treatment Market Overview, by Treatment Type Segment 32

6.1.1. Australia Addiction Treatment Market Revenue Share, By Treatment Type, 2023 & 2032 33

6.1.2. Australia Addiction Treatment Market Attractiveness Analysis, By Treatment Type 34

6.1.3. Incremental Revenue Growth Opportunity, by Treatment Type, 2024 – 2032 34

6.1.4. Australia Addiction Treatment Market Revenue, By Treatment Type, 2018, 2023, 2027 & 2032 35

6.2. Alcohol Addiction Treatment 36

6.3. Tobacco/Nicotine Addiction Treatment 37

6.4. Opioid Addiction Treatment 38

6.5. Other Substances Addiction Treatment 39

CHAPTER NO. 7 : AUSTRALIA ADDICTION TREATMENT MARKET – BY DRUG TYPE SEGMENT ANALYSIS 40

7.1. Australia Addiction Treatment Market Overview, by Drug Type Segment 40

7.1.1. Australia Addiction Treatment Market Revenue Share, By Drug Type, 2023 & 2032 41

7.1.2. Australia Addiction Treatment Market Attractiveness Analysis, By Drug Type 42

7.1.3. Incremental Revenue Growth Opportunity, by Drug Type, 2024 – 2032 42

7.1.4. Australia Addiction Treatment Market Revenue, By Drug Type, 2018, 2023, 2027 & 2032 43

7.2. Bupropion 44

7.3. Varenicline 45

7.4. Acamprosate 46

7.5. Disulfiram 47

7.6. Naltrexone 48

7.7. Methadone 48

7.8. Buprenorphine 49

7.9. Nicotine Replacement Products 49

7.10. Others 50

CHAPTER NO. 8 : AUSTRALIA ADDICTION TREATMENT MARKET – BY TREATMENT CENTER SEGMENT ANALYSIS 51

8.1. Australia Addiction Treatment Market Overview, by Treatment Centre Segment 51

8.1.1. Australia Addiction Treatment Market Revenue Share, By Treatment Center, 2023 & 2032 52

8.1.2. Australia Addiction Treatment Market Attractiveness Analysis, By Treatment Center 53

8.1.3. Incremental Revenue Growth Opportunity, by Treatment Center, 2024 – 2032 53

8.1.4. Australia Addiction Treatment Market Revenue, By Treatment Center, 2018, 2023, 2027 & 2032 54

8.2. Outpatient Treatment Centers 55

8.3. Residential Treatment Centers 56

8.4. Inpatient Treatment Centers 57

CHAPTER NO. 9 : AUSTRALIA ADDICTION TREATMENT MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 58

9.1. Australia Addiction Treatment Market Overview, by Distribution Channel Segment 58

9.1.1. Australia Addiction Treatment Market Revenue Share, By Distribution Channel, 2023 & 2032 59

9.1.2. Australia Addiction Treatment Market Attractiveness Analysis, By Distribution Channel 60

9.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 60

9.1.4. Australia Addiction Treatment Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 61

9.2. Hospitals Pharmacies 62

9.3. Medical Stores 63

9.4. Others 64

CHAPTER NO. 10 : COMPANY PROFILES 65

10.1. Teva Pharmaceutical Industries Ltd. 65

10.1.1. Company Overview 65

10.1.2. Product Portfolio 65

10.1.3. Swot Analysis 65

10.1.4. Business Strategy 66

10.1.5. Financial Overview 66

10.2. Pfizer, Inc. 67

10.3. Glenmark Pharmaceuticals 67

10.4. GSK plc 67

10.5. Johnson & Johnson Services, Inc. 67

10.6. Novartis AG 67

10.7. Cipla 67

10.8. Dr. Reddy’s Laboratories Limited 67

10.9. Mylan N.V. 67

10.10. Eli Lilly and Company 67

CHAPTER NO. 11 : RESEARCH METHODOLOGY 68

11.1. Research Methodology 68

11.1.1. Phase I – Secondary Research 69

11.1.2. Phase II – Data Modeling 69

Company Share Analysis Model 70

Revenue Based Modeling 70

11.1.3. Phase III – Primary Research 71

11.1.4. Research Limitations 72

Assumptions 72

List of Figures

FIG NO. 1. Australia Addiction Treatment Market Revenue, 2018 – 2032 (USD Million) 17

FIG NO. 2. Porter’s Five Forces Analysis for Australia Addiction Treatment Market 23

FIG NO. 3. Company Share Analysis, 2023 24

FIG NO. 4. Company Share Analysis, 2023 25

FIG NO. 5. Company Share Analysis, 2023 25

FIG NO. 6. Company Share Analysis, 2023 26

FIG NO. 7. Australia Addiction Treatment Market – Company Revenue Market Share, 2023 27

FIG NO. 8. Australia Addiction Treatment Market Revenue Share, By Treatment Type, 2023 & 2032 33

FIG NO. 9. Market Attractiveness Analysis, By Treatment Type 34

FIG NO. 10. Incremental Revenue Growth Opportunity by Treatment Type, 2024 – 2032 34

FIG NO. 11. Australia Addiction Treatment Market Revenue, By Treatment Type, 2018, 2023, 2027 & 2032 35

FIG NO. 12. Australia Addiction Treatment Market for Alcohol Addiction Treatment, Revenue (USD Million) 2018 – 2032 36

FIG NO. 13. Australia Addiction Treatment Market for Tobacco/Nicotine Addiction Treatment, Revenue (USD Million) 2018 – 2032 37

FIG NO. 14. Australia Addiction Treatment Market for Opioid Addiction Treatment, Revenue (USD Million) 2018 – 2032 38

FIG NO. 15. Australia Addiction Treatment Market for Other Substances Addiction Treatment, Revenue (USD Million) 2018 – 2032 39

FIG NO. 16. Australia Addiction Treatment Market Revenue Share, By Drug Type, 2023 & 2032 41

FIG NO. 17. Market Attractiveness Analysis, By Drug Type 42

FIG NO. 18. Incremental Revenue Growth Opportunity by Drug Type, 2024 – 2032 42

FIG NO. 19. Australia Addiction Treatment Market Revenue, By Drug Type, 2018, 2023, 2027 & 2032 43

FIG NO. 20. Australia Addiction Treatment Market for Bupropion, Revenue (USD Million) 2018 – 2032 44

FIG NO. 21. Australia Addiction Treatment Market for Varenicline, Revenue (USD Million) 2018 – 2032 45

FIG NO. 22. Australia Addiction Treatment Market for Acamprosate, Revenue (USD Million) 2018 – 2032 46

FIG NO. 23. Australia Addiction Treatment Market for Disulfiram, Revenue (USD Million) 2018 – 2032 47

FIG NO. 24. Australia Addiction Treatment Market for Naltrexone, Revenue (USD Million) 2018 – 2032 48

FIG NO. 25. Australia Addiction Treatment Market for Methadone, Revenue (USD Million) 2018 – 2032 48

FIG NO. 26. Australia Addiction Treatment Market for Buprenorphine, Revenue (USD Million) 2018 – 2032 49

FIG NO. 27. Australia Addiction Treatment Market for Nicotine Replacement Products, Revenue (USD Million) 2018 – 2032 49

FIG NO. 28. Australia Addiction Treatment Market for Others, Revenue (USD Million) 2018 – 2032 50

FIG NO. 29. Australia Addiction Treatment Market Revenue Share, By Treatment Center, 2023 & 2032 52

FIG NO. 30. Market Attractiveness Analysis, By Treatment Center 53

FIG NO. 31. Incremental Revenue Growth Opportunity by Treatment Center, 2024 – 2032 53

FIG NO. 32. Australia Addiction Treatment Market Revenue, By Treatment Center, 2018, 2023, 2027 & 2032 54

FIG NO. 33. Australia Addiction Treatment Market for Outpatient Treatment Centers, Revenue (USD Million) 2018 – 2032 55

FIG NO. 34. Australia Addiction Treatment Market for Residential Treatment Centers, Revenue (USD Million) 2018 – 2032 56

FIG NO. 35. Australia Addiction Treatment Market for Inpatient Treatment Centers, Revenue (USD Million) 2018 – 2032 57

FIG NO. 36. Australia Addiction Treatment Market Revenue Share, By Distribution Channel, 2023 & 2032 59

FIG NO. 37. Market Attractiveness Analysis, By Distribution Channel 60

FIG NO. 38. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 60

FIG NO. 39. Australia Addiction Treatment Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 61

FIG NO. 40. Australia Addiction Treatment Market for Hospitals Pharmacies, Revenue (USD Million) 2018 – 2032 62

FIG NO. 41. Australia Addiction Treatment Market for Medical Stores, Revenue (USD Million) 2018 – 2032 63

FIG NO. 42. Australia Addiction Treatment Market for Others, Revenue (USD Million) 2018 – 2032 64

FIG NO. 43. Research Methodology – Detailed View 68

FIG NO. 44. Research Methodology 69

List of Tables

TABLE NO. 1. : Australia Addiction Treatment Market: Snapshot 17

TABLE NO. 2. : Drivers for the Australia Addiction Treatment Market: Impact Analysis 20

TABLE NO. 3. : Restraints for the Australia Addiction Treatment Market: Impact Analysis 22

Frequently Asked Questions:

What is the projected growth of the Australia addiction treatment market?

The Australia addiction treatment market is projected to grow from USD 78.44 million in 2023 to an estimated USD 149.42 million by 2032, with a compound annual growth rate (CAGR) of 7.24% from 2024 to 2032.

What factors are driving the growth of the addiction treatment market in Australia?

Key drivers include increasing awareness about addiction, advancements in treatment methodologies, integration of technology in treatment programs, and rising prevalence of substance abuse disorders.

How are government initiatives influencing the addiction treatment market?

Government initiatives and funding are expanding access to treatment, improving the quality of care, and supporting ongoing research into effective interventions, significantly driving market growth.

What role does technology play in the addiction treatment market?

Technology, particularly telemedicine and mobile health applications, enhances accessibility and convenience, allowing patients to receive treatment and support remotely, which is crucial for those in underserved areas.

Who are the key players in the Australia addiction treatment market?

Industries Ltd., Pfizer, Inc., Glenmark Pharmaceuticals, GSK plc, Johnson & Johnson Services, Inc., Novartis AG, Cipla, Dr. Reddy Laboratories Limited, Mylan N.V., and Eli Lilly and Company. These companies drive innovation and expand their offerings to meet growing demand.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –